Conclusions. AEs in kidney transplant immunosuppression trials appear to be selectively reported and may be unreliable for clinical decisions. Adherence to the Consolidated Standards of Reporting Trials harms extension should be mandatory to ensure transparent reporting of AEs that are important to patients and clinicians.
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I N T R O D U C T I O N
Kidney transplantation improves survival and quality-of-life outcomes in many patients with end-stage kidney disease [1] . However, the side effects of maintenance immunosuppression following transplantation may have a detrimental effect on patient well-being and are associated with non-adherence, which can lead to graft loss [2] [3] [4] [5] [6] . The choice of maintenance immunosuppression after transplantation is largely based on improvements in acute rejection, graft function, graft loss and mortality from trial-based evidence [7] . The potential toxicities of these agents are considerable. Understanding the net benefits associated with a treatment regimen requires knowledge of adverse effects as well as benefits [8] .
Inadequate reporting of adverse events (AEs) in trials is well recognized [9] , and, in response, the harms extension of the Consolidated Standards of Reporting Trials (CONSORT) statement [10] was developed and widely adopted [11] . Similarly the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) group have developed a checklist for systematic reviews reporting harms [12] . An AE refers to any undesirable effect of an intervention, including serious outcomes and drug-related side effects [11, 13] . In trials of maintenance immunosuppression following kidney transplantation, reporting of harms such as infection, diabetes, cardiovascular disease and cancer, as well as quality of life, has been shown to be infrequent, incomplete and of poor quality [14] [15] [16] [17] [18] , whereas the reporting of drug-related side effects has not been assessed. Reporting of harms in clinical trials may be limited by the need for extended follow-up and the rarity of the harm [19] ; however, drug-related side effects generally occur within a short time frame and can affect a sizeable proportion of patients [20] . As noted by CONSORT 'randomized trials offer the best approach for providing safety data as well as efficacy data, although they cannot detect rare harms' [10] .
Patient-centered care relies on an unbiased understanding of the benefits and harms of an intervention, including the frequency and severity of drug-related side effects. As with benefits, knowledge of harms derives from the published reported outcomes of clinical trials. The aim of our study was to determine the completeness of reporting of AEs, specifically drug-related side effects, in published reports of randomized controlled trials of maintenance immunosuppression in kidney transplantation.
M A T E R I A L S A N D M E T H O D S

Literature search and inclusion criteria
We searched the Cochrane Kidney and Transplant Specialist Register from January 2003 to December 2015 for all randomized controlled trials of maintenance immunosuppression following kidney transplantation published in peer-reviewed Comparative trials between immunosuppressive medications, withdrawal/substitution of an immunosuppressive agent from multi drug regimens or variation in doses/schedules of one or more drugs were eligible. There was no restriction by language or age of recipients. Non-randomized trials and trials published only as abstracts (i.e. meetings and conferences) were excluded. As the focus of the review is on routinely used regimens, novel, experimental or discontinued immunosuppressive agent trials were excluded, as were patients undergoing multiple organ transplants.
Outcome measures
From eligible studies, all drug-related AEs, defined as any undesirable symptom or side effect, were included [11, 21] 
irrespective of whether the outcome was labeled as an adverse outcome, (serious or otherwise). However, as the focus of this study was on side effects directly related to drugs rather than outcomes that have a more complex causal pathway, we did not include harms such as malignancy, diabetes, cardiovascular disease or blood pressure and biochemical outcomes.
Appraisal of completeness of reporting of AEs
As there is no standardized tool for the assessment of quality of reporting of AEs, we used the approach recommended by Mahady et al. [13] in their review of AE reporting in systematic reviews. In this approach, the harms extension of the CONSORT statement [11] is used as a checklist for reporting quality since it 'captures many aspects such as clearly defining AEs, providing numerical data on incidence, and recording methods of data collection' [13] . The checklist consists of 23 criteria covering 10 domains addressing definition of AEs, methodology of data collection and reporting (see Supplementary data, Table S1 ). Each trial that reported relevant AEs was reviewed against the checklist and compliance was recorded as yes, no or not applicable. A formal AEs reporting quality score for each study was not calculated, as the purpose of the review is to identify deficiencies with respect to completeness and reliability of reporting rather than overall compliance. For trials reported in multiple publications, the full text of each report was reviewed and only those reporting unique AEs were selected for review against the checklist.
Data extraction and synthesis
A standardized spreadsheet was used by two researchers (M.H. and R.Y.) to extract characteristics for trials and AE outcomes. As AEs may not be reported in the first trial publication and later reports may include AEs, all trial publications were reviewed to capture all AEs for that trial. A trial was identified as not reporting AEs if no details about any AE were available from all publications of that trial. For each trial reporting AEs, the AE(s) at the level of detail provided was recorded. For example, gastrointestinal symptoms may be reported as a gastrointestinal disorder or as specific symptoms such as diarrhea and nausea. Where an AE was not FIGURE 2: AEs reported plotted as the proportion of the 163 trials that reported at least one AE. 'Adverse events', 'nervous system disorders', 'general disorders', 'pain (not defined)', 'psychiatric disorders' and 'appearance disorders' are all unspecified.
associated with a specific symptom or, for example, reported simply as an 'adverse event' or 'pain', it was recorded as 'not defined'. The types of AEs reported by trials were recorded as a binary outcome.
We evaluated the characteristics of trials that we postulated may be associated with the completeness of reporting AEs based on similar studies undertaken in other disciplines [13, 19, [22] [23] [24] [25] [26] . Characteristics included the source of funding, type of intervention, trial setting, study population (adults/children), year of publication, size of the trial, duration of the trial and journal type (specialist transplant, specialist nephrology, other). Associations between these characteristics and reporting of AEs were assessed using univariable and multivariable logistic regression. Variables that had an association with the reporting of AEs at P < 0.20 in unadjusted analyses were included in the multivariable-adjusted analyses. The least significant variables were then removed from the base model using a stepwise backward elimination process until only variables with P < 0.05 remained in the final parsimonious model. All calculations were undertaken using SPSS version 22 software (IBM, Armonk, NY, USA) on the basis of the number of trials rather than publications.
R E S U L T S
Characteristics of included trials
Overall, 314 reports of 233 trials including 45 896 patients fulfilled the inclusion criteria ( Figure 1) . One hundred and fifty-six (67%) trials were industry funded, 198 (85%) enrolled only adult kidney transplant recipients and 133 (58%) focused on interventions involving calcineurin inhibitors (CNIs) ( Table 1) . Most trials were relatively small, with 143 (61%) including <150 participants, and of short duration, with 145 (62%) being <24 months of follow-up.
AEs
A total of 163 (70%) trials including 36 523 (80%) patients, published in 197 reports, reported at least one AE (Table 1) . Of these trials, 22 (13%) reported AEs in more than one report.
Overall, 40 different types of AEs were reported, ranging from 1 to 22 [mean 4.9 (SD 4.0)]. The most frequently reported were gastrointestinal symptoms in 116 (71%) trials, ranging from 58% of the 26 steroid-focused trials to all of the 21 mycophenolate and all of the 4 belatacept trials (Figure 2 ; Supplementary data, Table S2, Figure S1 ). The next four most commonly reported AEs were peripheral oedema [55 (34%)], skin disorders [42 (26%)], nonspecified 'adverse events' [38 (23%)] and tremor [37 (23%)]. Of the 40 AEs reported, 26 (65%) were reported in <16 (10%) trials. Five AE types were generic or non-specified, namely, 'adverse events', 'nervous system disorders', 'general disorders', 'pain (not defined)', 'psychiatric disorders' and 'appearance change', and were reported in 72 (44%) trials. Other poorly defined categories were reproductive and rectal disorders, reported in less than four trials. Figure 2 shows the frequency of AE types reported across all 163 trials and Supplementary Table S2 and Figure S1 show the breakdown according to intervention drugs. The most frequently reported AEs in the CNI trials (n ¼ 90; 18 913 patients) were gastrointestinal disorders (61%), peripheral edema (39%), skin disorders (28%), tremor (24%), gingival overgrowth (24%) and non-specified AEs (23%). Paresthesia, a common and known side effect, was reported in only 3% of the trials and no trial reported anxiety, aggression or mood swings. All mycophenolate trials (n ¼ 21; 4235 patients) reported gastrointestinal disorders; with the next most common being nonspecified AEs (14%), pain (headache) (14%), pain (abdominal) (14%) and gingival overgrowth (10%). In mechanistic target of rapamycin inhibitor (mTORi) trials (n ¼ 24; 6497 patients) the most commonly reported AEs were gastrointestinal disorders (92%), peripheral oedema (58%), skin disorders (46%), oral (other than gingival overgrowth) (42%) and pain (musculoskeletal) (33%). All belatacept trials (n ¼ 4; 1297 patients) reported gastrointestinal disorders and tremor, while peripheral oedema was reported in 75% of the trials. All of the eight remaining AEs were reported in one trial. The most commonly reported AEs in the steroid-sparing trials (n ¼ 24; 5581 patients) were gastrointestinal disorders (58%), undefined 'adverse events' (46%), tremor (25%), skin disorder (21%), and pain (musculoskeletal) (21%) which is similar to the CNI trials, consistent with cyclosporine (CsA) or tacrolimus (Tac) being common to the interventions in these trials. 
Predictors for reporting
The association between trial characteristics and the odds of reporting AEs in trials are summarized in 
Completeness of reporting
Compliance with the harms extension of CONSORT for the 163 trials reporting AEs is summarized in Figure 3 . The lowest area of compliance was found in domains relating to the definition, measurement and collection of AEs (domains 3 and 4). Only 24 (15%) of the trials listed the AEs, 17 (10%) provided justification, 17 (10%) provided definitions, 27 (17%) measured severity, 8 (5%) described the instrument and 13 (8%) described the method of collection and whether the event was patient, clinician or researcher reported. Less than half of all studies [n ¼ 63 (39%)] described the methodology for presentation and analysis of AEs (item 5). The majority [n ¼ 146 (90%)] of trials provided quantitative data, with 118 (72%) tabulating AEs, and 134 (82%) reported separate results for each trial arm. No studies undertook subgroup analysis (item 9). Despite the majority reporting withdrawal [n ¼ 130 (80%)], 53 (33%) gave no reasons for withdrawal. AEs were included in the discussions of 129 (79%) of the trials (item 10a) and in 79 (48%) trials AEs were judged to have influenced the conclusions (item 10b) either positively or negatively. [20, 27] . However, we have shown that this is not reflected in the reporting of AEs in trials of these interventions, with about a third of all trials not reporting any drug-related AE. Without access to the individual patient study data we are unable to determine whether this is because no AEs were experienced by any participating patient or whether AEs were either not measured or reported (or both). The former explanation is implausible, and so we can conclude there is substantial underreporting of drug-related AEs. Of concern, there does not appear to be any improvement over time, but industry funding, multicenter design and publication in a specialist transplant journal increase the likelihood of reporting at least one AE. Furthermore, trials that reported AEs were deficient in a number of important areas, including providing definitions and/or justification for the AEs reported, measurement and definition of severity and describing the methodology used to measure or collect the AEs. Despite the lack of justification and detail on definition and methodology, AEs were included in discussions of nearly 80% of the trials and were judged to have influenced the conclusions, either positively or negatively, in just under half.
Outcomes were reported heterogeneously, with 40 different types of AEs recorded. Of these, 26 were reported in <10% and 16 in <2% of trials reporting AEs. Gastrointestinal disorders were the most frequently reported AE (70% of the trials). The reporting within trials for single classes of drugs suggests selective reporting and/or recording of AEs. For example, in the CNI trials, 36 different AEs were reported, with 21 (58%) reported in <10% of the trials. In trials focused on mycophenolate, gastrointestinal disorders were reported in all trials, with only three other AEs reported in >10% of these trials.
The frequency of reporting of AEs casts further doubt on the reliability of reporting and whether the reporting provides an appropriate reflection of drug-related side-effect profiles. Moreover, while gastrointestinal disorders were most frequently reported, unspecified AEs such as 'adverse event' or 'psychiatric disorder' accounted for almost half (44%) of all AEs reported, which further limits the value of the data. The deficiencies in reporting have implications when interpreting results as an absence of an AE reported in a trial, as this may reflect a true absence or failure to measure and/or report a potentially relevant finding.
The most frequently occurring outcomes in reviews of observational studies are unusual hair growth, acne, muscle weakness, bruising, sleeplessness, depression, fear/anxiety, tremors, gum disorders, swollen/painful joints, fatigue and impotence [20, 27] . The top 10 most frequent symptoms reported in a 2009 review of five kidney transplant observational studies did not include gastrointestinal disorders, the most frequently reported in our review [20] . However, diarrhoea was recorded as the fifth most distressful symptom in one study. These findings are inconsistent with the AEs recorded in our review and further suggest underreporting in randomized controlled trials.
The harms extension of CONSORT was published in 2004 in response to empiric studies that highlighted inadequacies in AE reporting [11, 19] . Subsequent systematic reviews continued to show inadequacies across a range of disciplines. For example, reviews of 60 randomized trials on interventions for persistent depressive disorder [25] [19] all showed major deficiencies in reporting with no evidence of improvement with time. Similar findings have been reported for trials in gastroenterology [13] , cancer drug trials [26, 28] and urology [22] and for trials published in high-impact journals [29] . Many studies have noted the subsequent impact of poor AE reporting on systematic reviews and meta-analyses [13, [30] [31] [32] [33] . As a consequence, the PRISMA group developed an extension to address the reporting of harms and approaches to identifying selective versus incomplete reporting in systematic reviews [12] .
A particular strength of our study was that all of the published reports of randomized controlled trials of maintenance immunosuppression were subject to full-text review, thus Nonetheless, AEs are difficult to search for, being either secondary or ad hoc outcomes [30, 34] , and may not be indexed or easily found using text words. To address this, the criteria for exclusion of studies from full-text review were limited to meetings and conferences and duplicates. The search dates included trials that started before publication of the CONSORT harms extension, thus compliance with the checklist may provide a misleading assessment of reporting quality. The harms extension was published in 2004 [11] , and poorer compliance might be expected for trials published before 2007 given that most of these are likely to have commenced before 2004. Despite the time lag, compliance among trials published after 2007 remained poor, lacking reporting of key domains such as justification, definition and methodology. The majority of the trials in this review are of relatively short duration and AEs may not occur within the time frame of a trial [19] ; however, the focus of our review was on drug-related side effects that occur within a short time frame. Finally, because the study is based on published reports of randomized trials, and not on study protocols, the review is unable to identify how trials intended to measure, manage and report AEs. However, protocols are often not in the public domain and the focus of the review is on evidence available to researchers and clinicians.
C O N C L U S I O N S
It appears that reporting of AEs in randomized trials of immunosuppression following kidney transplantation is generally inadequate. AEs are often poorly defined and lack description of how they are measured, and expected common side effects are rarely reported. As a consequence, despite the large number of randomized trials, it is very difficult to draw meaningful conclusions as to the frequency and severity of side effects associated with current treatment regimens. This is of particular concern, as patients tend to underreport side effects to health care professionals, who may also underestimate the frequency and importance of side effects [35] [36] [37] . Maintenance immunosuppression following kidney transplantation relies on a relatively small number of drugs, which limits the range of options and choices available for individual patients. Nonetheless, balancing graft survival with the risk of serious adverse outcomes and potentially debilitating side effects necessitates review and adjustment of regimens. Transplant patients are willing to accept drug-related side effects as a necessary downside of maintenance immunosuppression [38] ; however, particularly in the context of shared decisions, this should be underpinned by knowledge of the likely frequency and severity of the side effects. Following the approach taken by Mahady et al. [13] , Table 3 provides a summary of key domains of the CONSORT harms extension that trials should address, at a minimum, in order to improve the reliability of reporting of AEs in trials of maintenance immunosuppression following kidney transplantation. Attention should be given to AEs that are commonly experienced or important to patients, as this can inform patient-centered clinical decisionmaking.
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